Inhibitors of ABC-type drug efflux pumps: An overview of the current patent situation

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 4, 2004, Pages 499-508

  Chiba, Peter ^a   Ecker, Gerhard F ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

ABC transport protein; Anticancer agents; Inhibitors of P glycoprotein; Multi drug resistance

Indexed keywords

5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; ABC TRANSPORTER; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BIRICODAR; COLCHICINE DERIVATIVE; CYCLOSPORIN; DEXNIGULDIPINE; DEXVERAPAMIL; DOXORUBICIN; ELACRIDAR; ETACRYNIC ACID; GLYCOPROTEIN P INHIBITOR; IMATINIB; IROFULVEN; LANIQUIDAR; NIGULDIPINE; ONT 093; QUINIDINE; SN 22995; TAMOXIFEN; TARIQUIDAR; TAXANE DERIVATIVE; TIMCODAR; TOREMIFENE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ANTINEOPLASTIC ACTIVITY; BACTERIAL INFECTION; BREAST CANCER; CLINICAL TRIAL; DOWN REGULATION; DRUG DESIGN; DRUG INDICATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; MYCOSIS; PATENT; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TUMOR RESISTANCE;

EID: 1842854619     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.4.499     Document Type: Review

References (16)

1. JULIANO RL, LING V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta (1976) 455:152-162.
2. AMBUDKAR SV, KIMCHI-SARFATY C, SAUNA ZE, GOTTESMAN MM: P-glycoprotein: from genomics to mechanism. Oncogene (2003) 22:7468-7485.
3. RADERER M, SCHEITHAUER W: Clinical trials of agents that reverse multi-drug resistance. A literature review. Cancer (1993) 73:3553-3563.
4. RAMACHANDRAN C, WELLHAM LL: Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multi-drug-resistant human tumor cell lines and xenografts. Anti-Cancer Res. (2003) 23:2681-2690.
5. TEODORI E, DEI S, SCAPECCHI S, GUALTIERI F: The medicinal chemistry of multi-drug resistance (MDR)-reversing drugs. Farmaco (2002) 57:385-415.
6. WIESE M, PAJEVA I: Structure-activity relationships of multi-drug resistance reversers. Curr. Med. Chem. (2001) 8:685-713.
7. AVANDANO C, MENENDEZ JC: Inhibitors of multi-drug resistance to antitumor agents (MDR). Curr. Med. Chem. (2002) 9:159-193.
8. KLOPMAN G, SHI LM, RAMU A: Quantitative structure-activity relationship of multi-drug resistance reversal agents. Mol. Pharmacol. (1997) 52:323-334.
9. SEELIG A: A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. (1998) 251:252-261.
10. EKINS S, KIM RB, LEAKE BF et al.: Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. (2002) 61:974-981.
11. PAJEVA I, WIESE M: Pharmacophore model of drugs involved in P-glycoprotein multi-drug resistance: explanation of structural variety (hypothesis). J. Med. Chem. (2002) 45:5671-5686.
12. REBITZER S, ANNIBALI D, KOPP S et al.: In silico screening with benzofurane- and benzopyrane-type MDR-modulators. Farmaco (2003) 58:185-191.
13. CHAN LM, LOWES S, HIRST BH: The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. (2004) 21:25-51.
14. MINDERMAN H, BROOKS TA, O'LOUGHLIN KL, OJIMA I, BERNACKI RJ, BAER MR: Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives orataxel (IDN-5109, BAY-8862) and tRA96023. Cancer Chemother. Pharmacol. (2004) 53:Jan 27 [Epub ahead of print].
15. GARRAWAY LA, CHABNER B: MDR1 inhibition: less resistance or less relevance? Eur. J. Cancer (2002) 38:2337-2340.
16. RENAU TE, LEGER R, FILONOVA L et al.: Conformationally restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomanas aeruginosa. Bioorg. Med. Chem. Lett. (2003) 13:2755-2758.